This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (31)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Paul F. Griner, MD; Leon W. Hoyer, MD

Arch Intern Med. 1970;125(2):328-332.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

Thrombocytopenia is a common feature of systemic lupus erythematosus (SLE). It is generally regarded as a manifestation of increased platelet destruction.^1-8 This conclusion is based upon the observation of normal to increased numbers of megakaryocytes on bone marrow examination, information from platelet survival and kinetic studies in patients with this disease,⁹ and a generally good response to treatment with steroids or splenectomy. The frequency of antibodies directed against tissue components in SLE offers a possible explanation for shortened platelet survival, although these antibodies have not been demonstrated in vitro. In striking contrast to the usual findings associated with thrombocytopenia in SLE are those we have recently observed in a young woman with this illness. Selective bone marrow aplasia with absence of megakaryocytes was documented in this instance. In addition, the survival of transfused platelets did not suggest immune destruction. To our knowledge, this observation has not been previously . . . [Full Text PDF of this Article]

Author Affiliations
Rochester, NY

From the Department of Medicine, University of Rochester (NY) School of Medicine and Dentistry.

Footnotes
Received for publication June 13, 1969; accepted Aug 7.

Reprint requests to 260 Crittenden Blvd, Rochester, NY 14620 (Dr. Griner).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?